Tolaney S, et al. MonarcHER: a randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of care chemotherapy in women with HR+, HER2+ advanced breast cancer. Abstract LBA23. ESMO Congress 2019, 29 sept. Barcelona, Spanje.
Invloed van snelle behandeling op overleving patiënten met vroeg stadium NSCLC
mei 2024 | Chirurgie, Longoncologie